AstraZeneca PLC (BCBA:AZN)
Argentina · Delayed Price · Currency is ARS | Market Cap | 445.34T +21.2% |
| Revenue (ttm) | 95.13T +7.3% |
| Net Income | 16.82T +17.4% |
| EPS | 2,970.38 +17.3% |
| Shares Out | n/a |
| PE Ratio | 26.09 |
| Forward PE | 17.47 |
| Dividend | 1,040.86 (1.34%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 1,045 |
| Open | 76,525 |
| Previous Close | 77,225 |
| Day's Range | 76,150 - 77,975 |
| 52-Week Range | 60,400 - 80,275 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
AstraZeneca price target raised to 18,900 GBp from 18,600 GBp at Citi
Citi analyst Graham Parry raised the firm’s price target on AstraZeneca (AZN) to 18,900 GBp from 18,600 GBp and keeps a Buy rating on the shares.
AstraZeneca price target raised to 17,000 GBp from 16,000 GBp at Barclays
Barclays raised the firm’s price target on AstraZeneca (AZN) to 17,000 GBp from 16,000 GBp and keeps an Overweight rating on the shares.
AstraZeneca price target raised to 15,250 GBp from 14,500 GBp at RBC Capital
RBC Capital raised the firm’s price target on AstraZeneca (AZN) to 15,250 GBp from 14,500 GBp and keeps an Outperform rating on the shares. The company’s solid Q3 performance underscores…
AstraZeneca: 3 Key Takeaways for Long-Term Investors
Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.
AstraZeneca chief Pascal Soriot eyes record £28m pay package bonanza
Pascal Soriot is already the highest-paid FTSE 100 chief executive, landing £17.7m last year at the Anglo-Swedish drugs giant.
AstraZeneca (AZN) Q3 2026 Earnings Call Transcript
Oncology and rare disease momentum offset cardiovascular headwinds.
AstraZeneca Q3 Earnings Call Highlights
AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, wh...
AstraZeneca Q3 Earnings Call Highlights
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by dou...
Friday's ETF Movers: PPH, PSI
In trading on Friday, the VanEck Pharmaceutical ETF is outperforming other ETFs, up about 2.4% on the day. Components of that ETF showing particular strength include shares of Astrazeneca, up about 7....
AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential
AstraZeneca stock gapped higher Friday as cancer drugs Enhertu and Tagrisso lent themselves to a solid third-quarter report.
AstraZeneca Earnings Call Transcript: Q3 2026
9M revenue grew 7% and core EPS 14%, led by oncology, rare disease, and R&I. A deep pipeline, including more than 20 planned 2027 Phase III readouts, supports the $80B 2030 ambition.
AstraZeneca Quarterly report: Q3 2026
AstraZeneca has published its Q3 2026 quarterly earnings report on October 30, 2026.
AstraZeneca Slides: Q3 2026
AstraZeneca has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
AstraZeneca CFO on AI, Earnings, Restructuring Plan
AstraZeneca Chief Financial Officer Aradhana Sarin says the drug company uses AI in almost every aspect of the work they do. She talks beating on earnings, their drug pipeline and how the company appr...
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall ...
AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan
AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker unveiled a programme to save $1.5 billion (€1.34bn) a year to invest back into d...
AstraZeneca launches overhaul to cut costs by £1.1bn a year
Anglo-Swedish AstraZeneca employs 100,000 workers globally, of which around 10,000 are based in the UK.
AstraZeneca CFO Aradhana Sarin on Q3 results, oncology portfolio and drug pipeline outlook
Aradhana Sarin, AstraZeneca CFO, joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's oncology portfolio, drug pipeline outlook, and more.
FTSE 100 Modestly Higher; AstraZeneca Rises On Strong Earnings
(RTTNews) - U.K. stock market's benchmark FTSE 100 moved higher Friday morning, supported by strong results from pharma major AstraZeneca and energy giant BP. Weakness in bank and mining stocks limite...
AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts; Stock Up
(RTTNews) - AstraZeneca PLC (AZN) on Friday reported higher third-quarter profit and revenue, supported by growth across its major therapy areas. The company reaffirmed its full-year revenue and core ...
FTSE 100 set for monthly gains; AstraZeneca up after results
London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
AstraZeneca reports Q3 core EPS $2.79
Reports Q3 revenue $16.21B, consensus $16B. The company said, ‘In the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14%, driven…
AstraZeneca backs FY26 core EPS view up low single digits
Backs FY26 revenue view up mid-to-high single digits. The company said, “AstraZeneca (AZN) reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER, based on the average foreign…
AstraZeneca Q3 Profit Rises; Reconfirms FY26 Revenue, Core EPS Guidance At CER
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) reported that its third quarter profit attributable to owners of the Parent increased to $3.12 billion from $2.53 billion, prior year. Diluted ...